Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more ...

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €175.00. The company’s shares closed last Friday at €168.20.

What is Pharma 4.0? The term Industry 4.0 refers to the fourth industrial revolution, associated with the application of advanced technologies that have dramatically changed the landscape of ...

Nodenza Venture Partners launchedFocus on international early-stage and pre-commercial biotech & medtech opportunitiesNew York, October 16, ...

After hours: October 18 at 4:04 PM EDT ...

Please use one of the following formats to cite this article in your essay, paper or report: APA Calluna Pharma. (2024, October 14). Calluna Pharma appoints Mark Gaffney as Chief Executive Officer ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

Feminist Women's Health Center employees Sincere Porter, Naomi Desta-Bell, Habeebah Yasin and Kwajelyn Jackson pose for a portrait following a vigil and rally for abortion rights and in response ...

The global pharmaceutical industry is growing and offers an attractive opportunity for investors. Well-established pharmaceutical stocks include AbbVie, Eli Lilly, Johnson & Johnson, and Pfizer.